Under the agreement, Abbott will develop a test to detect extra copies of the epidermal growth factor receptor gene using its proprietary fluorescence in situ hybridization technology in non-small cell lung cancer.
Stafford O’Kelly, vice president, molecular diagnostics, Abbott, said: “By helping to unlock the information found at the molecular level in each person’s DNA, we believe that molecular diagnostics hold the promise of personalized medicine. Our goal through this important technology is to improve the practice of medicine by helping to reduce risk, produce targeted cures, and improve the detection and prevention of serious illnesses.”